Skip to content
Screener

Insulet PODD Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$2.15M+105%
Medtronic logo
MedtronicMDT
-$888M+33.9%
Beta Bionics logo
Beta BionicsBBNX
$1.8M+4,188%
Embecta Corp. logo
Embecta Corp.EMBC
-$41.5M-11.3%
Opko Health logo
Opko HealthOPK
-$13.03M+83.6%

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Insulet’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001145197-26-000102
(in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Repurchase of common stock(300.0)
Proceeds from exercise of stock options0.42.5
Payment of withholding taxes in connection with vesting of restricted stock units(15.7)(21.2)
Net cash (used in) provided by financing activities(319.9)277.7
Effect of exchange rate changes on cash and cash equivalents(1.9)3.8
Net (decrease) increase in cash and cash equivalents(235.7)329.7
Cash and cash equivalents at beginning of period716.1953.4
Cash and cash equivalents at end of period$480.4$1,283.1

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's financing cash flow?
Insulet (PODD) reported financing cash flow of -$319.9M in Q1 2026.
How has Insulet's financing cash flow changed year-over-year?
Insulet's financing cash flow decreased by 215.2% year-over-year, from $277.7M to -$319.9M.
What is the long-term trend for Insulet's financing cash flow?
Over 2 years (2021 to 2025), Insulet's financing cash flow has grown at a 275.6% compound annual growth rate (CAGR), from $42.2M to -$595.3M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Insulet's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude